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ABSTRACT 
The object of this study was to compare vasorelaxing responses to propofol by the 
intrapulmonary artery (IPA) and the extrapulmonary artery (EPA), and to identify the 
mechanisms of action.  Rat pulmonary arterial rings were isolated and suspended in 
organ chambers where isometric tension development was measured under optimal 
resting tension.  All pulmonary arterial rings were pre-contracted with phenylephrine.  
Propofol (Diprivan™) and the vehicle (10% Intralipid™) were administered 
cumulatively in the presence or absence of N
ω
-nitro-L-arginine methyl ester (L-NAME).  
Sodium nitroprusside (SNP), a nitric oxide donor, was administered cumulatively.  
Propofol relaxed both EPA and IPA in a dose dependent manner (p<0.05), while the 
vehicle alone showed no effects.  The vasorelaxing responses to propofol were 
significantly higher in EPA than IPA at higher concentrations (10
-4
 M and 10
-4.5
M) 
(p<0.05), and were decreased by L-NAME in EPA (p<0.05), though it had no effect 
with IPA.  The concentration for SNP causing 50% relaxation was not significantly 
different between the two arteries.  We concluded that the response of smooth muscle 
to nitric oxide was the same between EPA and IPA, however, the vasorelaxing 
mechanisms of propofol seemed to be different between them at higher doses, 
suggesting that a mechanism exists and operates through the nitric oxide pathway.   
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INTRODUCTION 
Hypotension after propofol administration is not infrequent in clinical anesthesia, 
and one of the mechanisms is apparently associated with a decrease in systemic vascular 
resistance 
2)
.  However, the effect of protocol on pulmonary circulation is still 
controversial, as differences have been demonstrated among animal species and 
experimental methods 
1,3,4,6,9,13,14,18)
.   
Systemic vascular tone is modulated partly by a continuous release of nitric oxide 
(NO) 
10)
, and an active release of NO also maintains pulmonary vascular tone 
16)
.  
Petro, et al found that propofol stimulates NO release from cultured porcine endothelial 
cells 
14)
.  This may be one of the mechanisms assumed to induce hypotension and 
vasodilation after propofol administration.   
The pulmonary artery develops embryologically from two originating parts.  
One from the sixth aortic arch and the other from the lung bud.  Adrenergic nerve 
fibers are found in the extrapulmonary artery (EPA) arising from the sixth aortic arch, 
while no portion of the intrapulmonary artery (IPA) arising from the lung bud has any 
adrenergic innervation 
11)
.   
We hypothesized that vasorelaxing responses to propofol may depend on the 
pulmonary arterial regions, i.e., EPA and IPA.  Therefore, we investigated 
vasorelaxing responses to propofol in EPA and IPA, as well as the role of NO in the 
mechanisms of propofol-induced vasorelaxation of the pulmonary artery. 
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MATERIALS AND METHODS 
The study protocol was approved by the Animal Research Committee of the 
Research Facilities for Laboratory Animal Science at our institute.  Male Wistar rats 
(Charles River Japan Inc., Yokohama, Japan), 10-12 weeks old, weighing 330-450 g, 
were used.  They were anesthetized with intraperitoneal pentobarbital (50 mg/kg), and 
the lungs and heart were excised en bloc and placed in a modified Krebs-Henseleit 
solution [mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25.0, KH2PO4 1.2, 
dextrose 11, and ethylenediamine tetraacetic acid (EDTA) 0.026] at room temperature 
(approximately 25˚C).  Paired pulmonary arterial rings, from EPA and IPA, were 
isolated from the left lung and, after the connective tissue was cleaned off, were sliced 
into 3 mm in length ring segments.  The rings were suspended vertically for isometric 
tension recordings between two triangular hooks in organ chambers containing 20 ml of 
Krebs-Henseleit solution, and bubbled with a mixed gas containing 95% O2/5% CO2 at 
37˚C.  One hook was fixed at the bottom of the chamber and the other was connected 
to a force-displacement transducer (TB-611T, NihonKohden, Tokyo, Japan) through an 
amplifier (AP-601G, NihonKohden, Tokyo, Japan) and then to a digital recorder 
(Omniace RT3200, NEC San-ei, Tokyo, Japan). 
Active and resting tension relationships were obtained by increasing the resting 
tension, using a range of force from 0.25 to 2.0 g, according to the methods of Toda 
17)
.  
After equilibration of the resting tension, the rings were contracted with 60 mM of KCl 
to measure active tension.  The optimal resting tension was then determined with 1.5 g 
for EPA and 1.0 g for IPA.  A cumulative concentration-response curve to 
phenylephrine (10
-9
-10
-5.5 
M) was obtained under optimal resting tension.  The 
effective concentration that produced a 50% response (EC50) was determined to be 
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10
-7.29
 M for EPA and 10
-7.36
 M for IPA.  Therefore, we used 10
-7
 M of phenylephrine 
for the pre-contraction of EPA and IPA.  The rings were pre-contracted with 
phenylephrine, and cumulative concentration-response curves to propofol (10
-7
-10
-4 
M) 
were obtained by taking 10
-4 
M of papaverine-induced relaxation as 100%.  Since 
commercially available propofol (Diprivan™) is provided in a 10% Intralipid™ 
emulsion, we investigated the effects of 10% Intralipid™ as a vehicle.   
In order to measure the effects of sodium nitroprusside (SNP), some rings were 
also pre-contracted with phenylephrine, and cumulative concentration-response curves 
to SNP were determined.  The inhibitory concentration causing 50% relaxation of the 
contraction to phenylephrine (IC50) for SNP was calculated.  Other rings were 
pretreated with 300 µM of N
ω
-nitro-L-arginine methyl ester (L-NAME) 20 minutes 
before pre-contraction with phenylephrine, and then the cumulative 
concentration-response curve to propofol was obtained.  Finally, 10
-6
 M of 
acetylcholine chloride (ACh) was added, and the endothelium was confirmed to be 
intact. 
Krebs-Henseleit buffer, phenylephrine, L-NAME, papaverine, ACh, and EDTA 
were purchased from Sigma Chemical Co., St. Louis, USA, CaCl2 and NaHCO3 were 
from Katayama Chemical, Osaka, Japan, and Diprivan™ was from AstraZeneca 
Pharmaceuticals Japan, Osaka, Japan.  Intralipid™ was from Ohtsuka Pharmaceuticals, 
Tokushima, Japan. 
For statistical analysis, the effects of propofol and the vehicle were compared 
using ANOVA, followed by Scheffé‘s test.  The vasorelaxing responses to propofol 
between EPA and IPA were compared by a paired t-test, while the inhibitory effects of 
L-NAME with EPA and IPA were compared by an unpaired t-test.  The IC50 for SNP 
 6
was calculated by regression analysis and compared by an unpaired t-test using 
StatView 4.0, Abacus Concept, Inc., Berkeley, USA.  Statistical significance was 
considered when p was less than 0.05.  Values are expressed as mean±SEM.  N is the 
numbers of rats from which the pulmonary arterial rings were isolated. 
 
 
RESULTS 
Propofol caused vasorelaxing responses in both EPA and IPA in a dose dependent 
manner (p<0.05), while the vehicle solution showed none (Fig. 1).  The responses were 
significantly higher in EPA than IPA at high concentrations (10
-4
 M and 10
-4.5
M) 
(p<0.05) (Fig. 2).  The IC50 to SNP was determined to be 10
-8.28±0.25
 M for EPA and 
10
-8.21±0.24
 M for IPA.  SNP relaxed both EPA and IPA dose-dependently after 
pre-contraction with phenylephrine, while the IC50 was not significantly different 
between EPA and IPA.  After pretreatment with L-NAME, propofol relaxed EPA and 
IPA in the same manner as in Fig. 1.  Vasorelaxing responses to propofol were 
decreased by L-NAME in EPA (p<0.05), but not in IPA (Fig. 3). 
 
 
DISCUSSION 
We demonstrated that propofol relaxed pulmonary arteries dose-dependently, and 
that the vasorelaxing response to propofol was dependent on the region of the 
pulmonary artery.  L-NAME, an NO synthase (NOS) inhibitor, blunted the 
vasorelaxing responses to propofol in EPA, but not in IPA.  There were no differences 
in the vasorelaxing responses to SNP, a NO donor.  As a result, we considered that the 
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response of smooth muscle to NO was the same between EPA and IPA, however, the 
vasorelaxation mechanisms of propofol seem to be different between them, suggesting a 
mechanism through the NO pathway.   
The regulation of vascular constriction and dilation is classified into three major 
mechanisms, a neural mechanism, a humoral mechanism, and a local mechanism, which 
includes endothelial intervention 
11)
.  The neural mechanism and endothelial 
intervention were investigated in the present experimental model. 
Nerve terminals exist in the isolated arteries. Some adrenergic nerve fibers are 
found in EPA, however IPA has none of this type of innervation 
5)
.  Geiger, et al 
reported differential NO production in intrapulmonary arterial and aortic endothelial 
cells 
4)
, which mechanisms depend on inducible NOS.  It seems that both sympathetic 
innervation and endothelin-mediated vasodilation are different between EPA and IPA 
6)
.  
The pulmonary artery develops embryologically from two originating parts, one from 
the sixth aortic arch and the other from the lung bud.  The sixth aortic arch develops 
into EPA and the lung bud becomes IPA.  EPA has sympathetic innervation, while 
IPA does not 
5)
.  Vasodilation mediated by endothelin B receptor is more potent in 
EPA than IPA 
6)
.  From an embryological point of view, the vasodilation mechanism 
of propofol seems to be different between EPA and IPA.   
It is considered that the primary mechanism of vasodilation of volatile anesthetics 
is a decrease in the intracellular calcium concentration, while other mechanisms, 
including inhibition of protein kinase C and endothelium dependency, are presumed.  
It was previously demonstrated that propofol caused marked vasodilation in pulmonary 
arteries, though the propofol vehicle (Intralipid) had no effect 
13)
.  Thiopental and 
etomidate are direct pulmonary vasoconstrictors, and ketamine and propofol are direct 
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pulmonary vasodilators, while midazolam had no direct effects on isolated rat lung 
specimens 
15)
.  These effects on pulmonary vasculature do not vary with baseline 
pulmonary vascular tone, and only propofol has endothelium-dependent effects 
15)
.  
Propofol causes a release of NO from cultured porcine aortic endothelial cell 
14)
, which 
may account for the hypotension associated with propofol.  However, the duration of 
exposure to propofol would have been too short to activate inducible NOS activity in 
the present experiment.   
The effect of propofol is different depending on the region of vasculature, i.e., 
aorta or pulmonary artery 
4)
, species, and experimental methods, i.e., cultured cell 
14)
, 
isolated pulmonary arterial rings 
1,6,9,13)
, isolated lung perfusion 
3,18)
, and in vivo 
2)
.  
The effect of propofol with endothelium dependent and independent vasorelaxing 
mechanisms seems to still be controversial.  Other endothelium-derived relaxing 
factors, i.e. prostacyclin or endothelium-derived hyperpolarizing factor, were not 
investigated in this study. 
Park, et al found that the initial vasodilation in pulmonary arterial rings caused by 
30 or 100 µM propofol showed a gradual and partial recovery over 15 min, while that 
caused by 300 µM propofol showed constant and sustained vasodilation. They 
speculated from aortic rings study that propofol directly relaxed arterial smooth muscle, 
possibly inhibited NO production, and induced vasodilating cyclooxygenase metabolites 
13)
.  Hypoxic pulmonary vasoconstriction is preserved during ketamine anesthesia, but 
is potentiated during propofol anesthesia.  This potentiated response during propofol 
anesthesia appears to be caused by an inhibition of adenosine triphosphate-sensitive 
potassium channel-mediated pulmonary vasodilation 
12)
.  Propofol impairs the signal 
transduction pathway for acetylcholine-induced pulmonary vasodilation, which involves 
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the endothelial, but not the vascular smooth muscle, component of the response 
8)
.  The 
vasodilation is mediated by two components, NO and a cytochrome P450 metabolite, 
and propofol selectively attenuates the vasodilation by inhibiting both of these 
endothelium-derived mediators 
7)
.   
Although it is necessary to clarify the role of the NO pathway for understanding 
the vasoactivity of propofol, we could not use endothelial-denuded pulmonary artery 
specimens from rats.  Removal of the endothelium is technically difficult, because the 
pulmonary arterial wall is too thin for in vitro experiments.    
The concentration of propofol causing pulmonary vasorelaxation in this study 
was higher than in normal clinical use.  Vasorelaxing mechanisms through the NO 
pathway in EPA may partly play a role in pulmonary circulation in vivo.   
In conclusion, vasorelaxing responses to propofol were different depending on the 
region of the pulmonary artery, and one of the mechanisms is likely through the NO 
pathway in EPA. 
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FIGURE LEGEND 
Fig. 1: Rings were pre-contracted with 10
-7
 M of phenylephrine, and cumulative 
concentration-response curves to propofol (10
-7
-10
-4 
M) (n=9) and the vehicle solution (10% 
intralipid™) (n=8) were obtained. Propofol relaxed both EPA and IPA in a dose dependent 
manner (A and B, respectively), however, the vehicle solution had no effect on either. Data are 
given as mean ± SEM. EPA = extrapulmonary artery, IPA = intrapulmonary artery, % 
Relaxation = percentage obtained after taking 10
-4 
M of papaverine-induced relaxation as 100%. 
*p<0.05 versus % relaxation at 10
-7
 M of propofol. #p<0.05 versus vehicle. 
Fig. 2: Vasorelaxing responses to propofol by EPA and IPA specimens. Rings were 
pre-contracted with 10
-7
 M of phenylephrine and cumulative concentration-response curves to 
propofol (10
-7
-10
-4 
M) (n=9) were obtained. At higher concentrations of propofol (10
-4.5
 M or 
more), the degree of relaxation was higher in EPA than IPA. Data are presented as mean ± SEM. 
EPA = extrapulmonary artery, IPA = intrapulmonary artery, % Relaxation = percentage 
obtained after taking 10
-4 
M of papaverine-induced relaxation as 100%. *p<0.05 versus IPA. 
Fig. 3: Rings were pre-contracted with 10
-7
 M of phenylephrine, and cumulative 
concentration-response curves to propofol (10
-7
-10
-4 
M) were obtained in the presence or 
absence of 300 µM of L-NAME. Propofol dilated both EPA and IPA in a dose dependent 
manner after pretreatment with L-NAME. The vasorelaxing response to propofol in EPA was 
decreased by L-NAME (A); however, there was no effect in IPA (B).  Data are presented as 
mean ± SEM. EPA = extrapulmonary artery, IPA = intrapulmonary artery, L-NAME = 
N
ω
-nitro-L-arginine methyl ester, % Relaxation = percentage obtained after taking 10
-4 
M of 
papaverine-induced relaxation as 100%.  *p<0.05 versus % relaxation at 10
-7
 M of propofol. 
#p<0.05 versus control. 
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